Novartis Pharmaceuticals (NVS.US) Applies for Domestic Marketing Approval for "Siltuximab" for a New Indication

According to the Zhitong Finance and Economics APP, on May 12th, the official website of the Chinese Drug Evaluation Center (CDE) showed that Novartis Pharmaceuticals' secukinumab injection new indication application has been accepted. This is the sixth indication that this product has applied for listing in China, with a registration classification of 3.1, which means a foreign-produced biological product that is already marketed overseas but not yet marketed domestically applying for listing. Secukinumab is the world's first approved fully human interleukin (IL)-17A inhibitor, which specifically neutralizes IL-17A from multiple sources and inhibits its pro-inflammatory effects.